60 Degrees Pharmaceuticals, Inc. (SXTP)
0.9651
-0.05
(-5.38%)
USD |
NASDAQ |
Sep 02, 16:00
0.9651
0.00 (0.00%)
After-Hours: 19:31
60 Degrees Pharmaceuticals Research and Development Expense (TTM) : 2.329M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.329M |
| March 31, 2026 | 1.962M |
| December 31, 2025 | 2.088M |
| September 30, 2025 | 2.063M |
| June 30, 2025 | 2.194M |
| March 31, 2025 | 5.057M |
| December 31, 2024 | 4.986M |
| Date | Value |
|---|---|
| September 30, 2024 | 4.473M |
| June 30, 2024 | 3.796M |
| March 31, 2024 | 0.905M |
| December 31, 2023 | 0.6918M |
| September 30, 2023 | 0.6192M |
| June 30, 2023 | 0.4186M |
| March 31, 2023 | 0.6484M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Harrow, Inc. | 20.56M |
| ANI Pharmaceuticals, Inc. | 49.91M |
| Corcept Therapeutics, Inc. | 253.86M |
| Veru, Inc. | 11.76M |
| Johnson & Johnson | 15.06B |